Related Experiment Videos
[Randomized ergometric study of vasodilators combined with betablockaders]
Archives Des Maladies Du Coeur Et Des Vaisseaux
|February 1, 1986
Summary
Molsidomine, Nifedipine, and Risordan significantly improved exercise capacity in patients with stable angina on beta-blockers. Slow-release Trinitrin also showed benefits, suggesting effective vasodilator options for managing persistent effort ischemia.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable angina with persistent effort ischemia despite beta-blocker therapy is a clinical challenge.
- Optimizing vasodilator therapy in conjunction with beta-blockers is crucial for improving exercise tolerance.
Purpose of the Study:
- To compare the ergometric effects of various vasodilator drugs in patients with stable angina on beta-blocker therapy.
- To identify the most effective vasodilators for managing persistent effort-induced ischemia.
Main Methods:
- A randomized, single-blind, cross-over study involving 50 patients with stable angina.
- Two-by-two comparison of vasodilator drugs (Molsidomine, Risordan, Nifedipine, Lenitral, Langoran, Trinitrin) under basal and peak action conditions.
- Assessment of work to induce 1 mm ST depression (WST1) and maximum ST depression (ST max).
Main Results:
- Molsidomine, Risordan, and Nifedipine significantly improved both WST1 and ST max (p < 0.001).
- Lenitral, Langoran, and Trinitrin skin patch showed no significant improvement.
- Slow-release Trinitrin demonstrated significant improvements in WST1 and ST max at specific time points.
Conclusions:
- Molsidomine, Nifedipine, and Risordan are highly effective vasodilators when combined with beta-blockers for stable angina.
- Slow-release Trinitrin (2.5 mg) also shows promise as an adjunct therapy.
- These vasodilators can effectively manage persistent effort ischemia in patients on beta-blocker therapy.